<DOC>
	<DOCNO>NCT01396564</DOCNO>
	<brief_summary>HYPOTHESIS : Treatment pioglitazone effective reduce resistin concentration insulin resistance metformin child Type 2 Diabetes ( T2D ) . MATERIAL AND METHODS : Pediatric patient age 8-17 T2D define American Diabetes Association ( ADA ) include , treatment treat exclusively diet exercise receive anti-diabetic agent , well history insulin use apply insulin within 1 month initial visit . History T2D , hypertension , exercise , diet , age , gender somatometry record . A Blood sample take determine HbA1c , glucose , insulin resistin . STATISTICAL ANALYSIS : The percentual change 4 week analyzed concentration resistin , insulin resistance . Changes note week 12 , 24 , 36 48 resistin concentration , HbA1c HOMA value . Baseline final value compare paired test . Lineal logarithmic regression analysis use evaluate relationship homeostasis model assessment insulin resistance ( HOMA-IR ) resistin concentration . The statistical significance variable determine use ANOVA . The effect confound variable analyze test co-variance analysis . Statistical significance consider p &lt; 0.05 .</brief_summary>
	<brief_title>Pioglitazone Metformin Diabetic Children</brief_title>
	<detailed_description>At 2 week prior study subject meet dietician instruct consume weight-maintaining diet contain 50 % carbohydrate , 30 % fat , 20 % protein . During week prior start pioglitazone metformin treatment , subject come clinic 12 hr overnight fast clinical examination ( body weight , height , waist hip circumference ) biochemical test . All test do 8 10 . A general structure interview conduct . A questionnaire use obtain information demographic socioeconomic aspect . Anthropometric measurement obtain . Body weight measure 140-kg capacity floor scale , child stand center scale . Height obtain use floor scale 's stadiometer , child stand center scale . Height measure near 0.5 cm . Body weight measure record near 0.1 Kg . Body Mass Index ( BMI ) calculate weight ( Kg ) divide height ( m2 ) . Abdominal circumference measure near 0.1 cm level great frontal extension abdomen bottom rib cage top iliac crest . The equipment regularly calibrate use reference sample provide manufacturer . Baseline measurement resistin ( method ) insulin concentration ( method ) . At time , blood sample take liver function test , fast plasma glucose , lipid , HbA1c . All study perform 08:00 h follow 10-12 h overnight fast . Following completion study , subject randomize start pioglitazone metformin , 15 mg/day 850 mg respectively , 4 week period , subject return Clinical Pediatric Endocrinology 08:00 h , follow overnight fast , measurement fast plasma glucose concentration , body weight , blood pressure . Fasting plasma lipid ( total cholesterol , triglyceride , HDL cholesterol , LDL cholesterol ) measure . Fructosamine , HbA1c measure initial final week pioglitazone metformin treatment . Dietary adherence reinforce . After 4 week treatment , subject undergo measurement fast plasma glucose , resistin , insulin concentration .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Pediatric patient type 2 diabetes accord ADA . Patients previously receive antidiabetic treatment treat solely diet exercise receive one antidiabetic agent , apply insulin within 1 month study start . HbA1c &gt; 6.5 % &lt; 10 % . Stable body weight least 3 month study start . No intense exercise . Free infectious , chronic , acute inflammatory process 3 month prior study . Previous inform consent sign ( child parent guardian ) . Either sex 817 year old . Personal history type 1 diabetes Chronic renal failure serum creatinine 1.0 mg/dl . Active hepatic disease ( ALT AST 3 time normal ) Heart condition Acute chronic metabolic acidosis Receiving steroid insulin</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Resistin</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Insulin Resistance</keyword>
</DOC>